Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Checkpoint Therapeutics将参加H.C. Wainwright第二届BioConnect投资者大会
Download as PDF May 13, 2024
点击下载PDF2024年5月13日
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, taking place on Monday, May 20, 2024, at 12:30 p.m. ET. Checkpoint will also attend in-person one-on-one meetings during the conference.
驻马萨诸塞州沃尔瑟姆，2024年5月13日（全球新闻通讯社）——临床阶段的免疫疗法和靶向肿瘤公司Checkpoint Therapeutics, Inc.（“Checkpoint”）（Nasdaq: CKPT）今天宣布，总裁兼首席执行官James Oliviero将在纳斯达克举办的H.C. Wainwright第二届BioConnect投资者大会上参加炉边聊天，并在会议期间进行一对一的现场会议。
A webcast of the fireside chat will be available on the News & Events page, located within the Investors section of Checkpoint's website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days after the meeting.
该炉边聊天的网络直播将于Checkpoint网站的投资者板块内的新闻与事件页面（https://ir.checkpointtx.com/event-calendar/default.aspx）提供，之后大约可在30天内观看。https://ir.checkpointtx.com/event-calendar/default.aspx，之后大约可在30天内观看。
About Checkpoint Therapeutics
关于Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cSCC. Checkpoint is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib (formerly CK-101), a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.checkpointtx.com.
Checkpoint Therapeutics, Inc.是一家临床阶段的免疫疗法和靶向肿瘤公司，专注于收购、开发和商业化用于治疗实体瘤的新型治疗方法。 Checkpoint正在评估其主要抗体产品候选物cosibelimab，这是一种潜在的最佳PD-L1抗体，其许可来自达纳-法伯癌症研究所，作为治疗选定复发或转移性癌症（包括转移性和局部晚期的皮肤鳞状细胞癌）的潜在新疗法。Checkpoint也正在评估其主要的小分子靶向抗癌药物olafertinib（曾用名CK-101），这是第三代表皮生长因子受体（“EGFR”）抑制剂，作为一种潜在的治疗EGFR突变阳性非小细胞肺癌的新疗法。Checkpoint总部位于马萨诸塞州沃尔瑟姆市，由Fortress Biotech，Inc.（纳斯达克：FBIO）创立。欲了解更多信息，请访问www.checkpointtx.com。www.checkpointtx.com.
Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com
公司联系人：
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
（781）652-4500
ir@checkpointtx.com
Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com
投资者关系联系人：
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
（617）430-7577
arr@lifesciadvisors.com
Media Relations Contact:
Katie Kennedy
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com
媒体联系人：
Katie Kennedy
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com
Source: Checkpoint Therapeutics, Inc
来源：Checkpoint Therapeutics，Inc
Released May 13, 2024
发布于2024年5月13日
译文内容由第三方软件翻译。